XML 60 R47.htm IDEA: XBRL DOCUMENT
v3.24.0.1

REVENUES - Summary of Disaggregation of Revenues (Details) - USD ($) $ in Millions | 12 Months Ended
--- | ---
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | $ 27,116 | $ 27,281 | $ 27,305
U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 19,438 | 18,884 | 19,267
Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 4,310 | 4,469 | 4,874
Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 3,368 | 3,928 | 3,164
Product sales |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 26,934 | 26,982 | 27,008
Product sales | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 19,377 | 18,716 | 19,176
Product sales | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 4,197 | 4,342 | 4,678
Product sales | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 3,361 | 3,924 | 3,154
Total HIV |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 18,175 | 17,194 | 16,315
Total HIV | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 14,848 | 13,820 | 12,828
Total HIV | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 2,102 | 2,219 | 2,366
Total HIV | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 1,226 | 1,155 | 1,121
Biktarvy |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 11,850 | 10,390 | 8,624
Biktarvy | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 9,692 | 8,510 | 7,049
Biktarvy | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 1,253 | 1,103 | 969
Biktarvy | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 905 | 777 | 606
Complera/Eviplera |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 129 | 200 | 258
Complera/Eviplera | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 47 | 74 | 102
Complera/Eviplera | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 70 | 113 | 142
Complera/Eviplera | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 12 | 13 | 14
Descovy |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 1,985 | 1,872 | 1,700
Descovy | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 1,771 | 1,631 | 1,397
Descovy | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 100 | 118 | 164
Descovy | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 114 | 123 | 139
Genvoya |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 2,060 | 2,404 | 2,879
Genvoya | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 1,752 | 1,983 | 2,267
Genvoya | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 205 | 284 | 391
Genvoya | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 103 | 136 | 221
Odefsey |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 1,350 | 1,469 | 1,568
Odefsey | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 1,012 | 1,058 | 1,076
Odefsey | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 294 | 364 | 440
Odefsey | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 44 | 47 | 52
Stribild |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 101 | 127 | 189
Stribild | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 72 | 88 | 132
Stribild | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 21 | 29 | 43
Stribild | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 8 | 10 | 14
Truvada |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 114 | 147 | 371
Truvada | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 82 | 113 | 314
Truvada | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 13 | 15 | 22
Truvada | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 19 | 18 | 35
Revenue share - Symtuza |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 529 | 530 | 531
Revenue share - Symtuza | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 382 | 348 | 355
Revenue share - Symtuza | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 133 | 168 | 165
Revenue share - Symtuza | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 13 | 14 | 11
Other HIV |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 56 | 57 | 195
Other HIV | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 37 | 15 | 136
Other HIV | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 12 | 24 | 30
Other HIV | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 7 | 17 | 29
Total Oncology |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 2,932 | 2,139 | 1,251
Total Oncology | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 1,833 | 1,494 | 912
Total Oncology | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 875 | 573 | 303
Total Oncology | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 224 | 73 | 36
Total Cell Therapy |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 1,869 | 1,459 | 871
Total Cell Therapy | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 1,055 | 968 | 542
Total Cell Therapy | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 658 | 430 | 293
Total Cell Therapy | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 156 | 60 | 36
Tecartus |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 370 | 299 | 176
Tecartus | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 245 | 221 | 136
Tecartus | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 110 | 75 | 40
Tecartus | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 15 | 3 | 0
Yescarta |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 1,498 | 1,160 | 695
Yescarta | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 811 | 747 | 406
Yescarta | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 547 | 355 | 253
Yescarta | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 140 | 57 | 36
Trodelvy |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 1,063 | 680 | 380
Trodelvy | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 777 | 525 | 370
Trodelvy | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 217 | 143 | 10
Trodelvy | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 68 | 12 | 0
Total Liver Disease |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 2,784 | 2,798 | 2,850
Total Liver Disease | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 1,421 | 1,440 | 1,415
Total Liver Disease | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 511 | 525 | 525
Total Liver Disease | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 852 | 833 | 910
Total HCV |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 1,767 | 1,810 | 1,881
Total HCV | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 1,002 | 1,005 | 1,018
Total HCV | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 378 | 413 | 421
Total HCV | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 386 | 392 | 442
Ledipasvir/Sofosbuvir |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 70 | 115 | 212
Ledipasvir/Sofosbuvir | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 39 | 46 | 84
Ledipasvir/Sofosbuvir | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 12 | 17 | 31
Ledipasvir/Sofosbuvir | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 19 | 51 | 97
Sofosbuvir/Velpatasvir |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 1,537 | 1,530 | 1,462
Sofosbuvir/Velpatasvir | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 859 | 844 | 815
Sofosbuvir/Velpatasvir | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 323 | 355 | 316
Sofosbuvir/Velpatasvir | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 355 | 331 | 331
Other HCV |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 160 | 166 | 207
Other HCV | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 104 | 115 | 119
Other HCV | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 43 | 40 | 74
Other HCV | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 12 | 10 | 14
Total HBV/HDV |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 1,017 | 988 | 969
Total HBV/HDV | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 418 | 435 | 397
Total HBV/HDV | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 133 | 112 | 104
Total HBV/HDV | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 466 | 441 | 468
Vemlidy |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 862 | 842 | 814
Vemlidy | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 410 | 429 | 384
Vemlidy | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 38 | 35 | 34
Vemlidy | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 414 | 379 | 396
Viread |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 83 | 91 | 111
Viread | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 8 | 6 | 11
Viread | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 22 | 23 | 28
Viread | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 52 | 62 | 72
Other HB/HDV |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 72 | 55 | 44
Other HB/HDV | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 0 | 0 | 2
Other HB/HDV | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 72 | 55 | 42
Other HB/HDV | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 0 | 0 | 0
Veklury |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 2,184 | 3,905 | 5,565
Veklury | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 972 | 1,575 | 3,640
Veklury | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 408 | 702 | 1,095
Veklury | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 805 | 1,628 | 830
Total Other |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 859 | 946 | 1,027
Total Other | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 304 | 388 | 381
Total Other | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 301 | 323 | 389
Total Other | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 255 | 235 | 257
AmBisome |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 492 | 497 | 540
AmBisome | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 43 | 57 | 39
AmBisome | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 260 | 258 | 274
AmBisome | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 189 | 182 | 227
Letairis |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 142 | 196 | 206
Letairis | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 142 | 196 | 206
Letairis | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 0 | 0 | 0
Letairis | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 0 | 0 | 0
Other |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 225 | 253 | 281
Other | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 118 | 135 | 136
Other | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 40 | 65 | 115
Other | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 66 | 53 | 30
Royalty, contract and other revenues |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 182 | 299 | 297
Royalty, contract and other revenues | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 62 | 168 | 91
Royalty, contract and other revenues | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 114 | 127 | 196
Royalty, contract and other revenues | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | $ 7 | $ 4 | $ 10

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=gild_OtherInternationalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsStribildMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OncologyProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_CellTherapyProductsTotalCellTherapyProductSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_CellTherapyProductsTecartusMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsYescartaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_TrodelvyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_LiverDiseaseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HCVProductSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherHCVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_VekluryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsTotalOtherProductSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |